SCHEMBL5992669

SCHEMBL5992669

O=C(O)C1=CC(C(c2ccc(O)c(C(=O)O)c2)c2ccc(O)c(C(=O)O)c2)C=CC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGO2 Q9UKV8 1/20 1.00
C9 P02748 3/20 0.45
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 4/20 0.44
HSD17B10 Q99714 4/20 0.44
TDP1 Q9NUW8 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 3/20 0.44
GRM1 Q13255 1/20 0.44
HSPD1 P10809 2/20 0.43
THRB P10828 2/20 0.43
ALOX15 P16050 2/20 0.43
BRCA1 P38398 2/20 0.43
RECQL P46063 2/20 0.43
HSPE1 P61604 2/20 0.43
HIF1A Q16665 2/20 0.43
IKBKB O14920 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL976393 0.99 AGO2 (0.97) AGO2C9KDM4EALDH1A1HPGD
SCHEMBL2833452 0.68 KDM4E (0.62) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1649282 0.68 ALDH1A1 (0.62) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9755165 0.68 KDM4E (0.67) AGO2C9KDM4EALDH1A1HPGD
SCHEMBL14381820 0.67 KDM4E (0.61) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10370338 0.65 KDM4E (0.62) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11233617 0.64 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL11217868 0.64 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL8428483 0.63 CA1 (0.58) AGO2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL658651 0.63 KDM4E (0.56) AGO2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200121697-A1 METHODS FOR DIAGNOSING AND TREATING CACHEXIA AURIN BIOTECH INC. (CA) 2020-04-23 US claimed
EP-3630121-A1 METHODS FOR DIAGNOSING AND TREATING CACHEXIA Aurin Biotech Inc. (CA) 2020-04-08 EP claimed
WO-2018218357-A1 METHODS FOR DIAGNOSING AND TREATING CACHEXIA AURIN BIOTECH INC. (CA) 2018-12-06 WO claimed
US-20200121697-A1 METHODS FOR DIAGNOSING AND TREATING CACHEXIA AURIN BIOTECH INC. (CA) 2020-04-23 US disclosed
EP-3630121-A1 METHODS FOR DIAGNOSING AND TREATING CACHEXIA Aurin Biotech Inc. (CA) 2020-04-08 EP disclosed
US-20200064352-A1 Specific GNAI:GIV Interaction Screening Assays, Methods and Compositions UNIV CALIFORNIA (US) 2020-02-27 US disclosed
WO-2018218357-A1 METHODS FOR DIAGNOSING AND TREATING CACHEXIA AURIN BIOTECH INC. (CA) 2018-12-06 WO disclosed
WO-2012065139-A2 ENTPD5 INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200064352-A1 Specific GNAI:GIV Interaction Screening Assays, Methods and Compositions GNAI1, GNAI3, GNAI2 AGO2 4325/4885C9 2751/4885KDM4E 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.